The antimalarial drug, Ro 42-1611 (arteflene), does not affect cytoadherence and cytokine-inducing properties of Plasmodium falciparum malaria parasites.
The purpose of this study was to investigate the ability of the antimalarial drug, Ro 42-1611 to block parasite mediated cytokine induction in vitro as well as cytoadherence of infected erythrocytes to melanoma cells in vitro. The biological activity of Ro 42-1611 was confirmed as it blocked Plasmodium falciparum growth in cultures. Ro 42-1611, had no major effect on TNF, IL-alpha or IL-6 cytokine release from mononuclear cells stimulated with malaria antigens or lipopolysaccharide and it did not affect cell viability. Ro 42-1611 only slightly suppressed cytoadherence of infected erythrocytes to melanoma cells. The therapeutic effect of To 42-1611 appears to be confined to its parasite killing activity.
Dept. of Infectious Diseases, University Hospital (Rigshospitalet), University of Copenhagen, Denmark.
P H
PH
Jakobsen
T
T
Staalsø
K
K
Bendtzen
D
D
Stürchler
D000328:Adult; D000818:Animals; D000953:Antigens, Protozoan / Q000494:pharmacology; D000962:Antimalarials / Q000494:pharmacology*; D037621:Artemisinins; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002738:Chloroquine / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D004912:Erythrocytes / Q000187:drug effects / Q000469:parasitology; D006801:Humans; D007074:Immunoglobulin G; D007375:Interleukin-1 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000469:parasitology; D016778:Malaria, Falciparum / Q000097:blood* / Q000276:immunology; D015767:Mefloquine / Q000494:pharmacology; D008545:Melanoma; D010963:Plasmodium falciparum / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D013343:Styrenes / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000953:Antigens, Protozoan; D000962:Antimalarials; D037621:Artemisinins; D019086:Bridged Bicyclo Compounds, Heterocyclic; D016207:Cytokines; D007074:Immunoglobulin G; D007375:Interleukin-1; D015850:Interleukin-6; D008070:Lipopolysaccharides; D013343:Styrenes; D014409:Tumor Necrosis Factor-alpha; C090720:arteflene; D002738:Chloroquine; D015767:Mefloquine